d14f7871-db2f-423a-9e08-4ca84e452d61
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.200
- MYC_TARGETS_V2+0.200
- OXIDATIVE_PHOSPHORYLATION+0.200
- ANDROGEN_RESPONSE+0.100
- BILE_ACID_METABOLISM+0.100
- KRAS_SIGNALING_DN+0.100
- NOTCH_SIGNALING+0.100
- CHOLESTEROL_HOMEOSTASIS+0.000
- DNA_REPAIR+0.000
- E2F_TARGETS+0.000
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- INTERFERON_ALPHA_RESPONSE-0.500
- INTERFERON_GAMMA_RESPONSE-0.500
- ALLOGRAFT_REJECTION-0.400
- IL6_JAK_STAT3_SIGNALING-0.400
- INFLAMMATORY_RESPONSE-0.400
- ANGIOGENESIS-0.300
- COMPLEMENT-0.300
- GLYCOLYSIS-0.300
- IL2_STAT5_SIGNALING-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | e97f9781-5033-40bd-bc5c-7a703ef965b1 | — | — | 0.853 |
| 2 | R230 | — | — | 0.852 |
| 3 | ERR3262565 | — | — | 0.851 |
| 4 | 32a200c7-6f8a-4393-ae39-48c73b7935cf | — | — | 0.850 |
| 5 | TCGA-60-2716-01A-01R-0851-07 | — | cohortSQ1 | 0.841 |
| 6 | R16 | — | — | 0.841 |
| 7 | SRR8518365 | — | E | 0.839 |
| 8 | SRR5088853 | — | — | 0.836 |
| 9 | TCGA-56-7221-01A-11R-2045-07 | — | cohortSQ2 | 0.833 |
| 10 | s0112225 | — | — | 0.832 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 7 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |